Abstract
Background: Aberrant glomerular mesangial cell (MC) proliferation is a common finding in renal diseases. T-type calcium channels (T-CaCN) play an important role in the proliferation of a number of cell types, including vascular smooth muscle cells. The hypothesis that T-CaCN may play a role in the proliferation of human MC was investigated. Methods: The presence of T-CaCN in primary cultures of human MC was examined using voltage clamping and by RT-PCR. The effect of calcium channel inhibitors, and of siRNA directed against the Cav3.2 T-CaCN isoform, on MC proliferation was assessed using the microculture tetrazolium assay and nuclear BrdU incorporation. Results: Human MC express only the Cav3.2 T-CaCN isoform. Co-incubation of MC with a T-CaCN inhibitor (mibefradil, TH1177 or Ni2+) results in a concentration-dependent attenuation of proliferation. This effect cannot be attributed to direct drug-induced cytotoxicity or apoptosis and is not seen with verapamil, an L-type channel blocker. Transfection of MC with siRNA results in knockdown of T-CaCN Cav3.2 mRNA and a clear attenuation of MC proliferation. Conclusions: These results demonstrate for the first time an important role for T-CaCN in human MC proliferation. This could potentially lead to a novel therapy in the treatment of proliferative renal diseases.
References
1.
Schöcklmann HO, Lang S, Sterzel RB: Regulation of mesangial cell proliferation. Kidney Int 1999;56:1199–1207
[PubMed]
2.
Wenzel UO, Troschau G, Schoeppe W, et al: Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension. Hypertension 1992;20:233–241.
[PubMed]
3.
Harris DC, Hammond WS, Burke TJ, et al: Verapamil protects against progression of experimental chronic renal failure. Kidney Int 1987;31:41–46.
[PubMed]
4.
Aguas AP, Nickerson PA: Effect of verapamil on blood pressure and lesions in heart and kidney of rats made hypertensive by deoxycorticosterone. Am J Pathol 1983;110:48–54.
[PubMed]
5.
Moriyama T, Oka K, Ueda H, et al: Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes. Clin Exp Nephrol 2004;8:230–236
[PubMed]
6.
Perico N, Amuchastegui CS, Malanchini B, et al: Angiotensin-converting enzyme inhibition and calcium channel blockade both normalize early hyperfiltration in experimental diabetes, but only the former prevents late renal structural damage. Exp Nephrol 1994;2:220–228.
[PubMed]
7.
Bakris GL, Copley JB, Vicknair N, et al: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996;50:1641–1650.
[PubMed]
8.
Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–860.
[PubMed]
9.
Ono T, Liu N, Kusano H, et al: Broad antiproliferative effects of benidipine on cultured human mesangial cells in cell cycle phases. Am J Nephrol 2002;22:581–586.
[PubMed]
10.
Sugiura T, Imai E, Moriyama T, et al: Calcium channel blockers inhibit proliferation and matrix production in rat mesangial cells: possible mechanism of suppression of AP-1 and CREB activities. Nephron 2000;85:71–80.
[PubMed]
11.
Orth SR, Nobiling R, Bonisch S, et al: Inhibitory effect of calcium channel blockers on human mesangial cell growth: evidence for actions independent of L-type Ca2+ channels. Kidney Int 1996;49:868–879.
[PubMed]
12.
Guo W, Kamiya K, Kodama I, et al: Cell cycle-related changes in the voltage-gated Ca2+ currents in cultured newborn rat ventricular myocytes. J Mol Cell Cardiol 1998;30:1095–1103.
[PubMed]
13.
Xu X, Best PM: Postnatal changes in T-type calcium current density in rat atrial myocytes. J Physiol 1992;454:657–672.
[PubMed]
14.
Xu XP, Best PM: Increase in T-type calcium current in atrial myocytes from adult rats with growth hormone-secreting tumors. Proc Natl Acad Sci USA 1990;87:4655–4659.
[PubMed]
15.
Akaike N, Kanaide H, Kuga T, et al: Low-voltage activated calcium current in rat aorta smooth muscle cells in primary culture. J Physiol 1989;416:141–160.
[PubMed]
16.
Richard S, Neveu D, Carnac G, et al: Differential expression of voltage-gated Ca2+ currents in cultivated aortic myocytes. Biochem Biophys Acta 1992;1160:95–104.
[PubMed]
17.
Kuga T, Kobayashi S, Hirakawa Y, et al: Cell cycle-dependant expression of L- and T-type Ca2+ currents in rat aortic smooth muscle cells in primary culture. Circ Res 1996;79:14–19.
[PubMed]
18.
Brooks G, Harper JV, Bates SE, et al: Over-expression of the voltage-gated T-type calcium channel induces vascular smooth muscle cell proliferation (abstract). Circulation 1999;100:I–209.
[PubMed]
19.
Wang YQ, Brooks G, Yuan WZ, et al: Functional analysis of the human T-type calcium channel α1H subunit gene in cellular proliferation. Yi Chuan Xue Bao 2002;29:659–665.
[PubMed]
20.
Rodman DM, Reese K, Harral J, et al: Low-voltage-activated (T-type) calcium channels control proliferation of human pulmonary artery myocytes. Circ Res 2005;96:864–872.
[PubMed]
21.
Schmitt R, Clozel JP, Iberg N, et al: Mibefradil prevents neointima formation after vascular injury in rats: possible role of the blockade of the T-type voltage-operated calcium channel. Arter Thromb Vasc Biol 1995;15:1161–1165.
[PubMed]
22.
Haverstick DM, Heady TN, Macdonald TL, et al: Inhibition of human prostate cancer proliferation in vitro and in a mouse model by a compound synthesized to block Ca2+ entry. Cancer Res 2000;60:1002–1008.
[PubMed]
23.
Gray LS, Perez-Reyes E, Gamorra JC, et al: The role of voltage-gated T-type Ca2+ isoforms in mediating ‘capacitative’ Ca2+ entry in cancer cells. Cell Calcium 2004;36:489–497.
[PubMed]
24.
Chemin J, Monteil A, Briquaire C, et al: Overexpression of T-type calcium channels in HEK-293 cells increases intracellular calcium without affecting cellular proliferation. FEBS Lett 2000;478:166–172.
[PubMed]
25.
Sachs HG, Stambrook PJ, Ebert JD: Changes in membrane potential during the cell cycle. Exp Cell Res 1974;83:362–366.
[PubMed]
26.
Lee JH GJ, Cribbs LL, Perez-Reyes E: Nickel block of three cloned T-type calcium channels: low concentrations selectively block α1H. Biophys J 1999;3034–3042.
[PubMed]
27.
Hall DA, Carmines PK, Sansom SC: Dihydropyridine-sensitive Ca2+ channels in human glomerular mesangial cells. Am J Physiol Renal Physiol 2000;278:F97–F103.
[PubMed]
28.
Kahl CR, Means AR: Regulation of cell cycle progression by calcium/calmodulin-dependent pathways. Endocr Rev 2003;24:719–736
[PubMed]
29.
Zeng H, Liu Y, Templeton DM: Ca2+/calmodulin-dependent and cAMP-dependent kinases in induction of c-fos in human mesangial cells. Am J Physiol Renal Physiol 2002;283:F888–F894.
[PubMed]
30.
Welsby PJ, Wang H, Wolfe JT, et al: A mechanism for the direct regulation of T-type calcium channels by Ca2+/calmodulin-dependent kinase II. J Neurosci 2003;23:10116– 10121.
[PubMed]
31.
Honda M, Hayashi K, Matsuda H, et al: Divergent renal vasodilator action of L- and T-type calcium antagonists in vivo. J Hypertens 2001;19:2031–2037.
[PubMed]
32.
Ohishi M, Takagi T, Ito N, et al: Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study. Hypertens Res 2007;30:797–806.
[PubMed]
33.
Ishimitsu T, Kameda T, Akashiba A, et al: Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Hypertens Res 2007;30:621–626.
[PubMed]
34.
Sugano N, Wakino S, Kanda T, et al: T-type calcium channel blockade as a therapeutic strategy against renal injury in rats with subtotal nephrectomy. Kidney Int 2008;73:826–834.
[PubMed]
© 2009 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2009
You do not currently have access to this content.
